Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Rituximab in Relapsed/Refractory DLBCL
NCT01939327Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Sep 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Institut Paoli-Calmettes. Started Sep 2013; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01939327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939327.